Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects
Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects
This is a double-blind, randomized, placebo-controlled, dose-escalating, single dose and
 multiple dose study.
This is a double-blind, randomized, placebo-controlled, dose-escalating study. The study
 comprises single dose (Stage I) and multiple dose (Stage II) stages. Stage II will not be
 initiated until completion of Stage I. The interim safety analysis report will be submitted
 to TFDA for an approval for proceeding to Stage II.
Inclusion Criteria:

 Subjects may be entered in the study only if they meet all of the following criteria:

 1. Male with suitable veins for cannulation or repeated venipuncture, and must be able to
 swallow the study drug intact;

 2. Aged between 20 and 45 years (inclusive) at the screening visit;

 3. Has normal hematology results at screening visit;

 -  WBC: 3.54 ~ 9.06X10^3/μL

 -  RBC: 4 ~ 5.52X10^6/μL

 -  hemoglobin: 13.2 ~17.2 g/dL

 -  hematocrit: 40.4 ~ 51.1%

 -  platelet: 148 ~ 339X10^3/μL

 4. Has normal biochemistry results at screening visit;

 -  alkaline phosphatase: 34 ~ 104 U/L

 -  total bilirubin: 0.3 ~ 1.0 mg/dL

 -  AST: 8 ~ 31 U/L

 -  ALT: 0 ~ 41 U/L

 -  BUN: 7 ~ 25 mg/dL

 -  creatinine: 0.6 ~ 1.3 mg/dL

 5. Normal coagulation results at screening visit;

 -  Prothrombin time/INR: 9.8 ~ 11.5 sec/0.92 ~ 1.09

 -  PTT: 25.6~32.6 sec

 6. Normal blood pressure (systolic blood pressure: 100 ~ 140 mmHg; diastolic blood
 pressure: 60 ~ 90 mmHg) at screening visit or prior to administration of
 investigational product;

 7. Able to provide written informed consent and willing to comply with the study protocol
 procedures and restrictions.

 Exclusion Criteria:

 Subjects must not satisfy any of the following criteria:

 1. Has a body weight less than 50 kg and/or body mass index (BMI) less than 18 kg/m^2 or
 greater than 30 kg/m^2 at the screening visit. Body mass index is determined as total
 body weight/height^2 (kg/m^2);

 2. Is not in good general health as judged by the Investigator based on medical history,
 vital signs, physical examination, ECG, laboratory tests, and urinalysis at the
 screening visit or prior to administration of investigational product;

 3. Has a history or presence of any disease or condition known to interfere with the
 absorption, distribution, metabolism, or excretion of drugs at the screening visit or
 prior to administration of investigational product;

 4. Has a clinically significant psychiatric, renal, hepatic, cardiovascular,
 gastrointestinal, or neurologic disease at screening or prior to administration of
 investigational product;

 5. Is a smoker and/or has used nicotine-containing products within the last 6 months
 prior to the screening visit;

 6. Has a history of alcohol and/or drug abuse;

 7. Participation of any clinical investigation during the last 60 days;

 8. Blood donation of more than 250 mL within the past 12 weeks;

 9. Excessive intake of caffeine containing drinks or food (more than 6 units of caffeine
 per day). One caffeine unit is contained in the following items: 1 (177.4 mL) cup of
 coffee, 2 (354.9 mL) cans of cola, 1 (354.9 mL) cup of tea, ½ (118.3 mL) cup of energy
 drink (e.g., PAOLYTA B Liq. or WHISBIH Liq.) or 3 oz of chocolate;

 10. Use of drugs with enzyme inducing properties such as St. John's Wort within 4 weeks
 prior to dosing;

 11. Has used prescription or nonprescription medication (except for occasional use of
 paracetamol and nasal spray) or herbal remedies or vitamins or minerals within 2 weeks
 or 5 half-lives of the drug, whichever is longer, prior to dosing;

 12. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,
 or other products containing grapefruit or Seville oranges within 7 days of the first
 administration of study medication;

 13. Male subjects who are unwilling to use barrier contraception in addition to having
 their partner use another method of contraception, for the duration of the study and
 for 3 months after dosing;

 14. Has a positive result on screening for serum hepatitis B surface antigen (HBsAg),
 hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV);

 15. Has received a blood transfusion within the last 6 months at screening;

 16. Involved in the planning or conduct of the study.